Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A placebo-controlled, dose-ranging, randomized Phase 2 study of ALPN 303 in systemic lupus erythematosus (SLE) and potentially additional autoantibody-related diseases

Trial Profile

A placebo-controlled, dose-ranging, randomized Phase 2 study of ALPN 303 in systemic lupus erythematosus (SLE) and potentially additional autoantibody-related diseases

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs [90Y]Y-PentixaTher (Primary) ; Povetacicept (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Proof of concept
  • Acronyms RUBY-2
  • Sponsors Alpine Immune Sciences

Most Recent Events

  • 15 Nov 2023 According to an Alpine Immune Sciences media release, the company plans to initiate this study in 2H 2024.
  • 23 Mar 2023 According to an Alpine Immune Sciences media release, the company plans to launch this study in mid-2024, based on enabling data from the RUBY-3 and RUBY-4 studies.
  • 14 Nov 2022 According to an Alpine Immune Sciences media release, the company presented broad development plan including this study at the R&D Day on Sep 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top